US formulations income rose 2.2 per cent yr on yr to ₹3,739 crore, whereas European income elevated 27.4 per cent to ₹2,703 crore.
| Photograph Credit score:
iStockphoto
Aurobindo Pharma Ltd has posted a internet revenue of ₹910 crore for the quarter ended December 31, 2025, as in opposition to ₹846 crore in the identical quarter final yr, displaying a development of seven.6 per cent.
The corporate’s income stood at ₹8,646 crore (₹7,979 crore) within the quarter – up 8.4 per cent.
“The quarter mirrored regular execution throughout our core companies, supported by steady demand and the energy of our diversified product portfolio in key markets, together with the US and Europe,” Okay Nithyananda Reddy, Vice-Chairman and Managing Director of the corporate, mentioned in a press launch.
“Development remained measured, with continued deal with operational self-discipline and a balanced strategy to development and profitability. As we progress our strategic initiatives, we stay cautious but assured in our capacity to assist sustainable worth creation over the medium time period,” he mentioned.
US formulations income rose 2.2 per cent yr on yr to ₹3,739 crore, whereas European income elevated 27.4 per cent to ₹2,703 crore. The combination formulation income stood at ₹7,683 crore (₹6,960 crore), reflecting a ten.4 per cent development.
The corporate’s board of administrators authorized the proposal to accumulate a 26 per cent stake in Garuda Renewables Non-public Ltd for ₹66 crore and to enter into an influence buy settlement with the goal firm to acquire renewable vitality from hybrid wind-solar sources.
Printed on February 9, 2026
Source link
#Aurobindo #Pharma #PAT #crore
